北京地区2008~2014年膦甲酸钠不良反应分析

发布时间：2018-11-26 15:49

【摘要】：目的统计分析北京地区近6年来膦甲酸钠的不良反应报告,为膦甲酸钠的安全合理应用提供依据。方法收集2008年3月~2014年12月北京市药品不良反应监测中心数据库中膦甲酸钠不良反应报告,并对152例不良反应统计分析ADR报告类型、ADR发生时间、患者年龄、性别和民族分布、严重不良反应、过敏史、给药途径、剂型、用量、用药原因、患者既往ADR史、ADR累及器官/系统及表现、ADR关联性评价结果、ADR处理及预后。结果膦甲酸钠致ADR在31~60岁发生率较高,55.3%的ADR发生于用药后24 h内,临床表现复杂多样,涉及机体多个器官或系统,主要和严重的不良反应为肾损害及癫痫发作。结论膦甲酸钠的安全性是临床应关注的问题,应在合理使用的基础上,监测并及时处理其不良反应。
[Abstract]:Objective to analyze the adverse reactions of sodium phosphonate in Beijing in recent 6 years and to provide evidence for the safe and rational application of sodium phosphonate. Methods from March 2008 to December 2014, the adverse reaction reports of sodium phosphonate were collected from the database of Beijing Center for Monitoring adverse Drug reactions. The types of ADR reports, the time of occurrence of ADR, the age, sex and ethnic distribution of patients were analyzed statistically. Severe adverse reactions, history of allergy, route of administration, dosage, cause of drug use, past history of ADR, ADR involvement of organs / systems and manifestations, evaluation of ADR correlation, ADR treatment and prognosis. Results the incidence of ADR induced by phosphonium formate was high at the age of 31 ~ 60 years. 55.3% of ADR occurred within 24 hours after treatment. The clinical manifestations were complicated and varied, involving multiple organs or systems. The main and serious adverse reactions were renal damage and seizures. Conclusion the safety of phosphonium formate should be paid attention to in clinic, and its adverse reactions should be monitored and dealt with in time on the basis of rational use.
【作者单位】：中国医学科学院北京协和医学院北京协和医院;北京大学人民医院;煤炭总医院;北京市药品不良反应监测中心;
【基金】：国家临床重点专科建设项目
【分类号】：R969.3

【共引文献】